Amarin Corp Plc (AMRN)

[talleyville0311]

Not sure why this puts a smile on my face but it does.

"Amarin continues to expect the onset of the final primary cardiovascular event to occur in the second half of 2017 with publication of trial results likely in 2018. An independent Data Monitoring Committee (DMC) is expected to complete a protocol pre-specified interim efficacy and safety analysis after approximately 60% of the target aggregate primary cardiovascular events have occurred within the study. This interim analysis is most likely to occur in September 2016. A second interim efficacy and safety analysis with approximately 80% of the primary cardiovascular events is expected in mid-2017.

While it is possible that the study could terminate early for overwhelming efficacy at either the 60% or 80% interim analysis, guidelines for the independent DMC to recommend stopping the study for overwhelming efficacy require that the study achieve a high level of statistical significance on the primary endpoint and generate other robust findings including on certain, pre-specified secondary outcome measures to support an overall favorable benefit/risk profile. "

http://investor.amarincorp.com/releasedetail.cfm?ReleaseID=987206